Engineered for Severe Obesity and Complex Metabolic Disorders Retatrutides triple-agonist model is intended to help individuals with strong metabolic resistance, such as those who: plateau on semaglutide struggle with long-term weight maintenance experience rapid metabolic slowdown during dieting have severe insulin resistance or fatty liver issues Potential Beyond Weight Management Ongoing studies are exploring retatrutides ability to improve: insulin sensitivity liver-fat clearance cardiovascular risk markers inflammatory markers stabilization of long-term metabolic function These features suggest retatrutide may evolve into a broader therapeutic option than current GLP-1 drugs
The phase 2 trial data, for example, showed that participants on the highest doses of Retatrutide lost an average of nearly 25% of their body weight over 48 weeks
A beneficiary with a BMI of 32 and uncontrolled hypertension, or a BMI of 28 with pre-diabetes and a prior stroke, previously had no straightforward path to GLP-1 coverage
Retatrutide, because it adds glucagon receptor activation, may cause additional metabolic effects that neither semaglutide nor tirzepatide produce, including greater fat oxidation and potentially different hunger pattern changes
UKBiobank (2015)
10.1007/s00125-018-4737-5 55
